Key result
The addition of aliskiren /day to standard therapy did not improve left ventricular end-diastolic volume compared to standard therapy alone in patients with primary acute myocardial infarction.
Why the study?
Does aliskiren added to standard therapy improve left ventricular remodeling in patients with primary acute myocardial infarction?
Cohort (n=42)
Open-label
No
Does aliskiren added to standard therapy improve left ventricular remodeling in patients with primary acute myocardial infarction?
The addition of a low-dose direct renin inhibitor (aliskiren) to standard therapy including an ACEI or ARB did not attenuate left ventricular remodeling in patients with primary acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Aliskiren addition should not alter post-AMI care; leaves open whether renin inhibition affects remodeling in other settings or doses.
Some patients with acute myocardial infarction (AMI) have a poor prognosis due to left ventricular remodeling (LVR), resulting in the recurrence of congestive heart failure even when therapy with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II type 1 receptor blockers (ARBs) has been initiated. We investigated the effect of early administration of the direct renin inhibitor (DRI) aliskiren in combination with an ACEI or an ARB on LVR using cardiac magnetic resonance (CMR) imaging in patients with AMI.Twenty-one consecutive patients were treated with an ACEI or an ARB (non-DRI group), and another 21 consecutive patients received aliskiren 150 mg/day combined with an ACEI or an ARB (DRI group). CMR imaging was performed 7 days after AMI and 10 months later.CMR imaging revealed no significant changes in LV end-systolic volume, LV end-diastolic volume, or LV ejection fraction between the patients with and without DRI aliskiren. In the DRI group, plasma renin activity was significantly lower in both the acute and chronic phases; however, aldosterone levels were significantly lower in the acute but not the chronic phase.A low dose of aliskiren may be insufficient to maintain suppression of aldosterone under current standard therapies with an ACEI or an ARB and β-blocker in patients with primary AMI, and results in no attenuation of LVR.
No takes yet. Share an insight, caveat, or question.
Ozaki et al. (2014) conducted a cohort in Primary Acute Myocardial Infarction (n=42). Aliskiren vs. ACEI or ARB alone was evaluated on Change in left ventricular end-diastolic volume (LVEDV) at 10 months (p=0.436). The addition of aliskiren /day to standard therapy did not improve left ventricular end-diastolic volume compared to standard therapy alone in patients with primary acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: